Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 45
Filter
2.
Article in Russian | MEDLINE | ID: mdl-35485070

ABSTRACT

The resolution of the Council of Experts devoted to the discussion of the effectiveness of the use of a combination of rivaroxaban 2.5 mg 2 times a day and acetylsalicylic acid 100 mg per day to prevent recurrent non-coronary ischemic stroke results of the COMPASS study is presented. The advantages of this combination and the safety of its use are considered. Recommendations for the implementation of the results of the study in clinical practice are given.


Subject(s)
Rivaroxaban , Stroke , Aspirin/therapeutic use , Drug Therapy, Combination , Humans , Rivaroxaban/therapeutic use , Stroke/therapy
3.
Article in Russian | MEDLINE | ID: mdl-34481441

ABSTRACT

Nonsteroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants (MR) are successfully used to relieve pain, both in monotherapy and in combinations. The use of fixed drug combinations not only greatly facilitates daily clinical practice and increases patient adherence, but due to the potentiation of pharmacological effects, it allows to achieve better treatment results. This paper presents 3 clinical cases of successful inpatient use of a fixed combination of diclofenac 75 mg and orphenadrine 30 mg in the form of an infusion solution (NEODOLPASSE) for relief of acute back musculoskeletal pain syndrome.


Subject(s)
Acute Pain , Diclofenac , Acute Pain/drug therapy , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Diclofenac/therapeutic use , Humans , Orphenadrine/therapeutic use , Pain Measurement
4.
Vestn Otorinolaringol ; 86(2): 73-81, 2021.
Article in Russian | MEDLINE | ID: mdl-33929156

ABSTRACT

The goal of this paper is to review the pharmacological profile of betahistine and evidence for using it in the treatment of common vestibular disorders. Betahistine is a weak agonist for histamine H1 receptors and strong antagonist for histamine H3 receptors. It demonstrates the maximum benefit in different types of peripheral vertigo, especially in Meniere's disease. The best results in decreasing intensity of vertigo, frequency of attacks and stimulation of vestibular compensation were obtained in daily dose 48 mg during 3 months. In benign paroxysmal positional vertigo betahistine is used to treat residual dizziness after successful treatment of otolithiasis and to reduce the severity of vertigo during repositioning maneuvers. In vestibular neuritis betahistine stimulates central compensation during vestibular rehabilitation. A new once-daily drug formulation of modified-release betahistine is non-inferior to traditional and has a comparable safety profile, and could improve patient adherence. The implication of betahistine in the treatment of central vestibular disorders is under-researched. The efficacy of betahistine in increasing of vestibular compensation in post-stroke central vestibular disorders, persistent postural-perceptual dizziness and its role in vestibular migraine need further investigation.


Subject(s)
Meniere Disease , Vestibular Diseases , Benign Paroxysmal Positional Vertigo , Betahistine , Dizziness/etiology , Humans , Meniere Disease/diagnosis , Meniere Disease/drug therapy , Vestibular Diseases/diagnosis , Vestibular Diseases/drug therapy
5.
Article in Russian | MEDLINE | ID: mdl-31793548

ABSTRACT

According to rough estimates, at least one third of the population in developed countries suffers, to varying degrees, from certain forms of primary headache, the modern pharmacotherapy of which is not always effective and has a number of limitations. The non-pharmacological treatment of headache can be an alternative to the prescription of pharmacological agents and the only possible assistance option for patients developing drug-resistant cephalalgias. This review describes various methods of electrical neuromodulation that are used for the management of primary headaches. The authors provide information on current stages in implementation of implantable and non-invasive equipment into clinical practice, which makes possible electrical stimulations of peripheral nerves and of the sphenopalatine ganglion, as well as allows transcranial magnetic stimulation. Also the appearance and usage of portable electrical devices available on the world market are described, and mechanisms that can underlie anticephalgic action of neuromodulation therapy are discussed. Special attention is paid to the methods that are applied for electrostimulation of the vagus nerve and occipital nerves.


Subject(s)
Electric Stimulation Therapy , Headache , Transcranial Magnetic Stimulation , Headache/therapy , Humans , Peripheral Nerves , Vagus Nerve
6.
Article in Russian | MEDLINE | ID: mdl-30040813

ABSTRACT

Migraine is the third most common disease in the world. The overall prevalence of migraine in the Russian Federation is estimated at 20% with an estimated global prevalence of 14.7%. Migraine affects mostly people of working age and has a significant negative impact on the quality of life, the level of adaptation, ability to work, social functioning. Migraine represents a significant social and economic burden for patients and society as a whole. A team of national experts on migraine offers a program to prioritize quality of management of patients with headache.


Subject(s)
Migraine Disorders , Quality of Life , Headache , Humans , Prevalence , Russia
7.
Article in Russian | MEDLINE | ID: mdl-29460899

ABSTRACT

AIM: To study the parameters of vestibular evoked myogenic potentials (VEMPs) in different types of vertigo. MATERIAL AND METHODS: Seventy-seven patients, 35 men and 42 women, aged 43.7±12.5 years, with vestibular vertigo and unsteadiness were examined. The activity of the stemocleidomastoid muscle in response to auditory stimulation of the ipsilateral ear was recorded using surface electromyography. RESULTS: There were a trend towards the increase in the N2 latency, the significant reduction of the P1-N2 amplitude (p<0,005) on both sides and significant changes in the coefficient of asymmetry. Compared to healthy people, the P1 latency and asymmetry in P1 latency were significantly increased in patients with peripheral type of vertigo (p<0,005 and р=0,0007, respectively). There were no differences in the P1 latency and N2 in patients with unsteadiness. CONCLUSION: In patients with peripheral vertigo, central vertigo and unsteadiness, vestibular-spinal reflex was disturbed at different levels of vestibular analyzer.


Subject(s)
Vertigo/diagnosis , Vertigo/physiopathology , Vestibular Evoked Myogenic Potentials , Acoustic Stimulation , Adult , Electromyography , Female , Humans , Male , Middle Aged
9.
Zh Nevrol Psikhiatr Im S S Korsakova ; 117(1. Vyp. 2): 28-42, 2017.
Article in Russian | MEDLINE | ID: mdl-28514331

ABSTRACT

These recommendations on the diagnosis and treatment of migraine were elaborated by Russian headache experts in accordance with the evidence-based practice. Together with the latest classification, diagnostic principles and criteria of different clinical sub-forms the consensus contains basic data on migraine epidemiology, pathophysiological mechanisms, differential diagnosis and most effective and evidence based approaches to pharmacological and non-pharmacological management of migraine patients.


Subject(s)
Migraine Disorders , Consensus , Diagnosis, Differential , Headache , Humans , Migraine Disorders/diagnosis , Migraine Disorders/therapy , Russia
10.
Article in Russian | MEDLINE | ID: mdl-27240041

ABSTRACT

UNLABELLED: Recurrent episodes of vertigo are one of the most frequent reasons of referrals for medical help. In the Russian medicine, the development of vertigo is traditionally associated with a cerebral vascular pathology. It is suggested that correctly planned clinical neurovestibular study may identify the signs of a balance disorder of peripheral and central genesis. OBJECTIVE: To increase the effectiveness of the differential diagnosis of peripheral and central vertigo in patients with recurrent episodes of balance disorders using the protocol of neurovestibular examination ALGORITM. MATERIAL AND METHODS: The study included 120 outpatients with preliminary diagnoses of cerebral ischemia and autonomic vascular dystonia. RESULTS: Signs of lesion of peripheral and central regions of the vestibular system were found in 43.5 and 17.5% patients, respectively. Benign positional vertigo was the most frequent cause of vertigo while chronic cerebral ischemia was identified in 16.5% of the patients. CONCLUSION: Neurovestibularexamnation using the protocol ALGORITM is important for assessment of the level of vestibular system lesion. Iitis necessary to use it in complex examination of patients with complaints of vertigo.


Subject(s)
Benign Paroxysmal Positional Vertigo/diagnosis , Adult , Aged , Aged, 80 and over , Benign Paroxysmal Positional Vertigo/etiology , Brain Ischemia/complications , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Russia , Vestibule, Labyrinth/physiopathology , Young Adult
16.
Zh Nevrol Psikhiatr Im S S Korsakova ; 111(10 Pt 1): 44-6, 2011.
Article in Russian | MEDLINE | ID: mdl-22500312

ABSTRACT

Noopept is a neuroprotector and nootropics. Literature data revealed the treatment effect of noopept on mild cognitive impairment in patients with discirculatory encephalopathy. The present open prospective study included 60 patients with stroke treated with noopept during 12 months. Cognitive functions were assessed before and after treatment using neuropsychological tests. An analysis of MMSE scores and lateral and categorical associations revealed the significant improvement of cognitive functions after 2 months in patients of the main group compared to the controls. The global assessment of efficacy revealed the mild improvement in the main group while no changes were found in the control group. The results have demonstrated that noopept, used in dose 20 mg daily during 2 months, improves cognitive functions in stroke patients and has a high level of safety.


Subject(s)
Cognition Disorders/drug therapy , Dipeptides/therapeutic use , Neuroprotective Agents/therapeutic use , Stroke/complications , Aged , Aged, 80 and over , Cognition Disorders/etiology , Dipeptides/administration & dosage , Female , Humans , Male , Middle Aged , Neuroprotective Agents/administration & dosage , Treatment Outcome
19.
Eksp Klin Farmakol ; 71(5): 3-7, 2008.
Article in Russian | MEDLINE | ID: mdl-19093363

ABSTRACT

There is extensive clinical evidence for the high efficacy of GABA-ergic drugs in prophylactic and abortive treatment of migraine and cluster headache, while the mechanisms of anticephalgic drugs action are not clear, in particular, because of insufficient number of investigations on experimental headache models. In this study, the influence of baclofen (i.v.) in doses 2.5, 5, 10, and 15 mg/kg and valproate (i.v.) in doses 25, 50, 100, and 200 mg/kg on the background activity of the trigeminal nucleus caudalis neurons and that evoked by electrical stimulation of the superior sagittalis sinus was investigated in series of acute experiments on rats. It is established, that baclofen and valproate reduce both the background and evoked activity of trigeminal complex neurons in dose-dependent manner, thus determining the role of GABA-A and GABA-B receptors in realization of this effect. These results provide experimental basis for explanation of the clinical efficacy of the GABA-positive drugs in vascular headaches.


Subject(s)
Baclofen/pharmacology , GABA Agonists/pharmacology , Headache/metabolism , Neurons/metabolism , Superior Sagittal Sinus/metabolism , Valproic Acid/pharmacology , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Electric Stimulation , Headache/drug therapy , Headache/physiopathology , Rats , Rats, Wistar , Receptors, GABA-A/metabolism , Receptors, GABA-B/metabolism , Superior Sagittal Sinus/physiopathology , gamma-Aminobutyric Acid/metabolism
20.
Article in Russian | MEDLINE | ID: mdl-18577934

ABSTRACT

Efficacy of antidepressants fluvoxamine, amitriptyline and transcranial electrostimulation of the brain in the treatment of chronic daily headache has been studied. Amitriptyline had the highest effect in dosage 50 mg daily but was not well tolerated by patients that resulted in that only 50% of them finished the study. Fluvoxamine had high efficacy and good tolerability in the treatment of chronic daily headache and medication overuse headache. Small dosages of amitriptyline and fluvoxamine potentiated the analgesic effect of transcranial electrostimulation of the brain. The combination of antidepressants with transcranial electrostimulation of the brain alleviated the negative effect of the withdrawal of overused analgesics and may be recommended for out-patient use.


Subject(s)
Adrenergic Uptake Inhibitors/therapeutic use , Amitriptyline/therapeutic use , Electric Stimulation Therapy/instrumentation , Fluvoxamine/therapeutic use , Headache/therapy , Selective Serotonin Reuptake Inhibitors/therapeutic use , Adult , Chronic Disease , Female , Headache/drug therapy , Humans , Male , Middle Aged , Skull
SELECTION OF CITATIONS
SEARCH DETAIL
...